Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up

Rusu, Darian; Carlier, Thomas; Colombié, Mathilde; Goulon, D.; Rousseau, N.; Berton‐Rigaud, Dominique; Jaffré, Isabelle; Campion, Loı̈c; Rousseau, Caroline

doi:10.3389/fmed.2015.00046

Cited by 11 publications

(9 citation statements)

References 37 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the diagnostic accuracy is found quite similar in current as well as previous studies. 22,25,26 Therefore, the effectiveness of combined PET with contrast enhanced CT is more helpful in patients monitoring with suspicious recurrence of ovarian cancer as well as raised/normal tumor markers than PET alone. The limitation of this study was that there was no clinical confirmation of all irregular 18FDG sites.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic accuracy of PET/CT scan in evaluation of clinically suspected recurrent ovarian cancer

Sultana

Shoukat²,

Nausheen³

et al. 2021

J Fatima Jinnah Med Univ

View full text Add to dashboard Cite

Background: Accurate evaluation of ovarian carcinoma is utmost important for effective management. PET/CT is reported to be effective in evaluation of suspected recurrence of ovarian carcinoma. This study aims to assess the accuracy of PET/CT in evaluation of recurrent ovarian cancer among clinically suspected cases with rising tumor marker or suspicious clinic-radiological findings. Patients and methods: This prospective cross-sectional study was conducted at Radiology department of Jinnah Postgraduate Medical Centre Karachi from 22nd April 2019 to 21st April 2020. Patients having age of 40 to 60 years and referred for PET scan with suspected recurrence of ovarian carcinoma were consecutively enrolled. Patients were suspected due to relevant history, clinical findings and initial imaging investigations with elevated CA-125 level. Results of 18FDG PET/CT scan was correlated with the raised tumor findings. The PET/CT scan showing abnormally elevated FDG take-up and higher SUV values than the background activity considered recurrence. Diagnostic accuracy of PET/CT was calculated taking raised tumor level as reference category. Results: Of 65 patients, median age was 50 (43-56) years. The findings showed positive cases in 57 (87.7%) while negative in 8 (12.3%) patients, whereas the findings of tumor marker showed raised tumor marker in 61 (93.8%) patients. Diagnostic accuracy of PET/CT showed sensitivity, specificity, positive predicted value, negative predated value, and overall diagnostic accuracy as 93.44%, 100%, 100%, 50%, and 93.85% respectively. Conclusion: A higher accuracy of PET/CT was observed in the diagnosis of recurrent ovarian cancer among clinically suspected cases, thus helping in devising an appropriate management plan by the treating physician.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic accuracy of PET/CT scan in evaluation of clinically suspected recurrent ovarian cancer

Sultana

Shoukat²,

Nausheen³

et al. 2021

J Fatima Jinnah Med Univ

View full text Add to dashboard Cite

show abstract

“…Undoubtedly, with increased CA125 (≥35) the diagnostic value of [ 18 F]FDG PET/CT has been well established in numerous studies on ovarian cancer [ 58 , 59 ]. Generally, it can be argued that [ 18 F]FDG PET/CT is a valuable detection method in suspected recurrent cases, and it acts as a viable prediction tool for the progression of advanced ovarian cancer ( Figure 4 ) [ 60 , 61 , 62 , 63 , 64 ]. Despite these beneficial aspects of [ 18 F]FDG PET/CT, however, this procedure doesn’t show reliable diagnostic value in the primary stages of ovarian cancer [ 55 ].…”

Section: Ovarian Cancermentioning

confidence: 99%

A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies

Vahidfar

Farzanefar

Ahmadzadehfar

et al. 2022

Cancers

View full text Add to dashboard Cite

Nuclear medicine is defined as the diagnosis and the treatment of disease using radiolabeled compounds known as radiopharmaceuticals. Single-photon emission computed tomography/computed tomography (SPECT/CT) and positron emission tomography/computer tomography (PET/CT) based radiopharmaceuticals have proven reliable in diagnostic imaging in nuclear medicine and cancer treatment. One of the most critical cancers that also relies on an early diagnosis is gynecological cancer. Given that approximately 25% of all cancers in developing countries are a subset of gynecological cancer, investigating this cancer subtype is of significant clinical worth, particularly in light of its high rate of mortality. With accurate identification of high grade distant abdominal endometrial cancer as well as extra abdominal metastases, 18F-Fluorodeoxyglucose ([18F]FDG) PET/CT imaging is considered a valuable step forward in the investigation of gynecological cancer. Considering these factors, [18F]FDG PET/CT imaging can assist in making management of patient therapy more feasible. In this literature review, we will provide a short overview of the role of nuclear medicine in the diagnosis of obstetric and gynecological cancers.

show abstract

“…Its usefulness comes into place also in relation to disease recurrence, where PET/CT seems to be superior to both conventional imaging (computed tomography (CT), magnetic resonance imaging abdominal and intravaginal ultrasound, chest X-ray) and the CA-125 assay in regard to both sensitivity and specificity, both in high-grade and low-grade carcinomas [22,23].…”

Section: Introductionmentioning

confidence: 99%

A Comparative Study between 18F-FDG PET/CT and Conventional Imaging in the Evaluation of Progressive Disease and Recurrence in Ovarian Carcinoma

et al. 2021

View full text Add to dashboard Cite

The aim of this study is to compare the efficiency of conventional imaging and 18F-FDG PET-CT in detecting progressive disease and recurrences over a period of one year (2018), in the case of ovarian cancer, and also to assess the importance of 18F-FDG PET/CT in changing the course of the treatment for these patients. This study included 29 patients diagnosed in various stages with ovarian carcinoma, most of them of epithelial origin. All patients were evaluated throughout their treatment using 18F-FDG PET/CT and various conventional techniques (computed tomography (CT), magnetic resonance imaging (MRI), abdominal and intravaginal ultrasound, chest X-ray). PET/CT was more useful and effective in our group of patients in detecting progressive disease compared with conventional imaging (37.93% vs. 17.24%) and also in establishing the recurrences (24.14% vs. 6.90%). Moreover, F18-FDG PET-CT led to a therapeutic change in 55.17% of the patients of our group, compared with only 17.24% after conventional imaging. This underlines the crucial aspect of the metabolic changes of tumors that should be assessed alongside the morphological ones, with PET-CT imaging remaining the only viable tool for achieving that at present. PET/CT with 18F-FDG represents one of the most important imaging techniques used in the diagnosis and management of ovarian carcinoma. Our results seem to fall in line with what other authors reported, indicating that 18F-FDG PET-CT is potentially gaining more ground in the management of ovarian carcinoma, by influencing therapeutic strategies and by being able to detect relapse and progression accurately.

show abstract

Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up

Cited by 11 publications

References 37 publications

Diagnostic accuracy of PET/CT scan in evaluation of clinically suspected recurrent ovarian cancer

Diagnostic accuracy of PET/CT scan in evaluation of clinically suspected recurrent ovarian cancer

A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies

A Comparative Study between 18F-FDG PET/CT and Conventional Imaging in the Evaluation of Progressive Disease and Recurrence in Ovarian Carcinoma

Contact Info

Product

Resources

About